BCMA CAR T-cell therapy arrives for multiple myeloma: a reality

被引：8
|
作者：
Cho, Shih-Feng [1 ,2 ,3 ,4 ]
Anderson, Kenneth C. [1 ,2 ]
Tai, Yu-Tzu [1 ,2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA
[3] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Kaohsiung, Taiwan
[4] Kaohsiung Med Univ, Coll Med, Fac Med, Kaohsiung, Taiwan
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2018年 / 6卷
基金：
美国国家卫生研究院;
关键词：
MATURATION ANTIGEN; REMISSIONS; RECEPTORS;
D O I：
10.21037/atm.2018.11.14
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Development of KITE-585: A fully human BCMA CAR T-cell therapy for the treatment of multiple myeloma
    Adams, Gregor B.
    Feng, Jun
    Ghogha, Atefah
    Mardiros, Armen
    Murakami, Jodi
    Phung, Tammy
    Rodriguez, Ruben
    Sievers, Stuart
    Spindler, Tassja J.
    Wiltzius, Jed
    Yarka, Clare
    Yoder, Sean C.
    Polverino, Tony
    CANCER RESEARCH, 2017, 77
  • [22] Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
    Roex, Gils
    Timmers, Marijke
    Wouters, Kristien
    Campillo-Davo, Diana
    Flumens, Donovan
    Schroyens, Wilfried
    Chu, Yiwei
    Berneman, Zwi N.
    Lion, Eva
    Luo, Feifei
    Anguille, Sebastien
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [23] Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
    Gils Roex
    Marijke Timmers
    Kristien Wouters
    Diana Campillo-Davo
    Donovan Flumens
    Wilfried Schroyens
    Yiwei Chu
    Zwi N. Berneman
    Eva Lion
    Feifei Luo
    Sébastien Anguille
    Journal of Hematology & Oncology, 13
  • [24] Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma
    Samur, Mehmet K.
    Fulciniti, Mariateresa
    Aktas-Samur, Anil
    Bazarbachi, Abdul Hamid
    Tai, Yu-Tzu
    Campbell, Timothy B.
    Petrocca, Fabio
    Hege, Kristen
    Kaiser, Shari
    Anderson, Kenneth
    Munshi, Nikhil C.
    BLOOD, 2020, 136
  • [25] Calvarium indentations in multiple myeloma and CAR T-cell therapy
    Munoz, Javier
    Larsen, Jeremy
    LANCET, 2022, 400 (10349): : 391 - 391
  • [26] Advances in CAR T-Cell Therapy for the Treatment of Multiple Myeloma
    Shah, Nina
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (06) : 316 - 318
  • [27] CAR T-cell therapy for relapsed or refractory multiple myeloma
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (06): : E297 - E297
  • [28] CAR T-cell therapy in multiple myeloma: mission accomplished?
    Rasche, Leo
    Hudecek, Michael
    Einsele, Hermann
    BLOOD, 2024, 143 (04) : 305 - 310
  • [29] Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
    Liang, Zhiyu
    Li, Ping
    Kang, Liqing
    Zhou, Lili
    Xu, Yang
    Ye, Shiguang
    Du, Juan
    Li, Bing
    Wang, Yiwen
    Yu, Lei
    Qian, Wenbin
    Liang, Aibin
    BLOOD ADVANCES, 2022, 6 (01) : 293 - 296
  • [30] Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
    Wang, Ying
    Li, Chunrui
    Xia, Jieyun
    Li, Ping
    Cao, Jiang
    Pan, Bin
    Tan, Xu
    Li, Hujun
    Qi, Kunming
    Wang, Xiangmin
    Shi, Ming
    Jing, Guangjun
    Yan, Zhiling
    Cheng, Hai
    Zhu, Feng
    Sun, Haiying
    Sang, Wei
    Li, Depeng
    Zhang, Xi
    Li, Zhenyu
    Zheng, Junnian
    Liang, Aibin
    Zhou, Jianfeng
    Xu, Kailin
    BLOOD ADVANCES, 2021, 5 (23) : 5290 - 5299
12345